CARB-X IS FUNDING SUMMIT THERAPEUTICS TO DEVELOP A NEW ANTIBIOTIC TO TREAT MULTIDRUG-RESISTANT INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)
CARB-X is awarding Summit Therapeutics, (NASDAQ: SMMT) headquartered in Cambridge, MA, USA, with its Discuva subsidiary located in Cambridgeshire, UK, up to US$4.1 million in non-dilutive funding to develop a first-in-class antibiotic to treat multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections including those caused by serious human pathogens such as Escherichia coli and Klebsiella pneumoniae. Under the award, Summit could receive additional funding of up to $3.7 million from CARB-X if project milestones are achieved, subject to available funds. The award will help the company progress the SMT-738 antibiotic project through preclinical and Phase 1a clinical development.
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!